Postprandial Lipids in IBS and Nutritional Treatment (PLINT)

This is an interventional prevention trial for IBS - Irritable Bowel Syndrome Read More

Inclusion Criteria:

• IBS patients that meet the Rome IV criteria + additional criteria specific for the diarrhea-predominant subtype, based on the most frequent self-reported stool types using the Bristol stool chart
• Male and female adults, aged 18-70 years;
• Having a Body Mass Index (BMI) between 18.5 and 30 kg/m2;
• Willing to keep a stable dietary pattern throughout the study.

Exclusion Criteria:

• Having a disease that may interfere with the outcomes of this study, such as a known autonomic disorder, inflammatory bowel disease, coeliac disease, cancer, dialysis patients, chronic kidney failure, depression or hypothyroidism.
• History of intestinal surgery (excluding appendectomy or cholecystectomy) or endometriosis.
• Use of medication that can interfere with the study outcomes, including codeine and antibiotics, as judged by the medical supervisor.
• Use of anticoagulants (as curcumin has inhibitory effects on platelet aggregation).
• Use of prebiotics and/or probiotics (should be stopped 4 weeks before the start of the study) and infrequent use of other supplements dedicated to bowel function improvements.
• Having swallowing problems with pills/capsules.
• Having a cow's milk allergy or other food allergies.
• If applicable: currently pregnant or breastfeeding, or intending to become pregnant during the study.
• Participation in another clinical trial at the same time.
• Student or employee working at Food, Health and Consumer Research from Food and Biobased Research, or Department of Human Nutrition & Health, Wageningen University.
• Alcohol intake ≥ 14 (women) or ≥ 28 (men) glasses of alcoholic beverages per week.
• Smoking and abuse of illicit drugs, soft drugs, and/or nitrous oxide.